Evidence map›Paper›PMID 39433718›Full record

ArticleAnnals of surgical oncology2025

Neoadjuvant Treatment with Changes in Chemotherapy Regimens According to Carbohydrate Antigen 19-9 Level for Resectable/Borderline Resectable Pancreatic Ductal Adenocarcinoma.

Daisuke Hashimoto, Sohei Satoi, So Yamaki, Shinji Nakayama, Nobuhiro Shibata, Kazuki Matsumura, Hidetaka Miyazaki, Yuki Matsui, Denys Tsybulskyi, Nguyen Thanh Sang and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Daisuke HashimotoDepartment of Surgery, Kansai Medical University, Hirakata City, Osaka, Japan.
Sohei SatoiDepartment of Surgery, Kansai Medical University, Hirakata City, Osaka, Japan. satoi@hirakata.kmu.ac.jp.
So YamakiDepartment of Surgery, Kansai Medical University, Hirakata City, Osaka, Japan.
Shinji NakayamaThird Department of Internal Medicine, Kansai Medical University, Hirakata City, Osaka, Japan.
Nobuhiro ShibataCancer Treatment Center, Kansai Medical University, Hirakata City, Osaka, Japan.
Kazuki MatsumuraDepartment of Surgery, Kansai Medical University, Hirakata City, Osaka, Japan.
Hidetaka MiyazakiDepartment of Surgery, Kansai Medical University, Hirakata City, Osaka, Japan.
Yuki MatsuiDepartment of Surgery, Kansai Medical University, Hirakata City, Osaka, Japan.
Denys TsybulskyiDepartment of Surgery, Kansai Medical University, Hirakata City, Osaka, Japan.
Nguyen Thanh SangDepartment of Surgery, Kansai Medical University, Hirakata City, Osaka, Japan.
Tsukasa IkeuraThird Department of Internal Medicine, Kansai Medical University, Hirakata City, Osaka, Japan.
Masashi KanaiCancer Treatment Center, Kansai Medical University, Hirakata City, Osaka, Japan.
Mitsugu SekimotoDepartment of Surgery, Kansai Medical University, Hirakata City, Osaka, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe response of carbohydrate antigen (CA) 19-9 to neoadjuvant therapy (NAT) for pancreatic ductal adenocarcinoma (PDAC) may contribute to outcomes. This study aimed to investigate the effect of changes in NAT regimens based on CA19-9 level.

methodsThis single-center retrospective study included patients with resectable/borderline resectable (R/BR)-PDAC undergoing NAT from 2008 to 2022. A CA19-9 level lower than 150 IU/mL after NAT was the criterion for resection. If the level did not decrease, the chemotherapy regimen was changed to satisfy the criterion. The patient cohort was divided into group A (satisfied criterion without changing chemotherapy), group B (did not receive chemotherapy change, could not satisfy the criterion), group C (received chemotherapy change, satisfied the criterion), and group D (received chemotherapy change, could not satisfy the criterion).

resultsThe study cohort included 283 patients. After first-line chemotherapy, 112 (39.6%) patients did not satisfy the criterion (groups B [n = 64], C [n = 32], and D [n = 16]). Of the 283 patients, 48 (17%) received a chemotherapy change (groups C and D). The patients in groups C and D showed significantly better overall survival (OS, 35.9 months) than the group B patients (25.7 months) (P = 0.035). The OS of the group C patients (63.8 months) was similar to the OS of the group A patients (n = 171: 56.3 months; P = 0.430). Multivariate analysis of the patients in groups B, C, and D identified chemotherapy change as an independent prognostic factor for OS and progression-free survival.

conclusionChanging the chemotherapy targeting the CA19-9 level can improve the outcome of R/BR-PDAC patients with poor biologic response to first-line NAT.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsCA-19-9 AntigenCarcinoma, Pancreatic DuctalNeoadjuvant TherapyPancreatic NeoplasmsAgedBiomarkers, TumorFemaleFollow-Up StudiesHumansMaleMiddle AgedPancreatectomyPrognosisRetrospective StudiesSurvival RateBiomarkers, TumorCA-19-9 AntigenCA19-9Neoadjuvant treatmentPancreatectomyPancreatic ductal adenocarcinomaSurgery

Identifiers

PMID39433718

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.